Treating an animal model of cystic fibrosis (CF) with Kalydeco (ivacaftor) during embryonic development and after birth revealed that early…
Articles by Patricia Inácio, PhD
Pseudomonas aeruginosa, the most common bacteria found in cystic fibrosis (CF) patients, uses a virus to go unnoticed by…
Removing a key metabolite called pyruvate from Pseudomonas aeruginosa and Staphylococcus aureus bacteria biofilms — two of the most…
A new study shows that bacteriophages, viruses that naturally infect bacteria, can be used to fight Pseudomonas aeruginosa, the most…
Cystic fibrosis (CF) patients in Australia age 12 and older, who have two copies of the F508del mutation in the CFTR gene (a copy…
Tobramycin, an antibiotic commonly used against Pseudomonas aeruginosa bacteria, reduces the bacteria’s load of virulence factors that impair the function of the…
Frazier Healthcare Partners has launched a new biopharmaceutical company called Recida Therapeutics, which will develop new therapies for serious…
Adults with cystic fibrosis, compared with healthy individuals, have poorer diet quality and increased accumulation of visceral adipose tissue, which is…
Throughout the past year, Cystic Fibrosis News Today has brought you daily coverage of important discoveries, treatment developments, clinical trials, and other…
Researchers at West Virginia University (WVU) are working to develop a vaccine against Pseudomonas aeruginosa, the highly treatment-resistant bacteria that are…